Royalty Pharma plc (RPRX) - Forward P/S Multiple

Corporate emblem and logo of Royalty Pharma (RPRX)

Royalty Pharma plc (RPRX) acquires royalty rights to drugs, leveraging deep expertise to compete with banks. The forward P/S ratio reflects market expectations, with the indicator reaching 3.00. The business model of acquiring patents creates the risk of overpayment, while the cost of capital and drug patent expiration dates pressure the share price.

Royalty Pharma - RPRX Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

RPRX (Royalty Pharma Investments): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Royalty Pharma|RPRX - Fair Value Consensus
- market capitalization indicators:
Market Capitalization Royalty Pharma Investments|RPRX - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Royalty Pharma|RPRX - Total Stockholders' Equity|Market Value to Book Value Ratio royaltypharma.com|RPRX - Aggregate Asset Value
- debt level and financial liquidity data:
Debt to Equity Royalty Pharma plc|RPRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Royalty Pharma plc|RPRX - Company Cumulative Debt|Debts to Book Capitalization Royalty Pharma Investments|RPRX - Company Long-Term Debts|Company Short-Term Debt Royalty Pharma|Quick Liquidity Indicator royaltypharma.com
- financial results and valuation multiples details:
RPRX - Profit After Payment of Taxes|Future Profit Royalty Pharma plc|RPRX - Market Cap to Earnings|Projected Price to Earnings Royalty Pharma Corp|RPRX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Royalty Pharma Investments|RPRX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Royalty Pharma|RPRX - Earnings per share for the trailing year|Quarterly EPS earnings growth royaltypharma.com|RPRX - Earnings growth in current year|Net earnings per share growth forecast for next year Royalty Pharma plc
- revenue and sales details:
RPRX - Company Sales Revenue|Company Projected Revenue Royalty Pharma|RPRX - Market Cap to Revenue|Forward P/S Multiple Royalty Pharma Investments
Initial company analysis:Royalty Pharma RPRX
Original product of royaltypharma.com

The forward P/S ratio determines the market value of a business relative to projected sales volume, measuring the premium investors pay for potential revenue growth. For Royalty Pharma plc (RPRX), this calculation is based on expected royalties from the sale of biopharmaceutical products for which the company acquired rights from developers. Analysis using the forward P/S metric allows for an assessment of whether the capitalization is aligned with current royalty inflow rates and confirms the long-term sustainability of capital.

Competitors of Royalty Pharma plc

Price-to-Projected Revenue Ratio Texas Pacific Land Corporation TPL|Forward Price to Sales VNOM|Black Stone Minerals Corp - Forward P/S Multiple|Northern Oil and Gas (NOG) - Forward Price-to-Revenue Multiple|DMLP: Forward P/S Multiple|Market Cap to Future Revenue Ratio sbr-sabine.com (SBR)|Price-to-Projected Revenue Ratio Vitesse Energy|PBT: Forward Price to Sales|Price-to-Projected Revenue Ratio TXO Energy (TXO)|GRNT - Market Cap to Future Revenue Ratio|XOMA Royalty Corporation - Forward Price-to-Revenue Multiple|San Juan Basin Royalty Trust Units (SJT) - Market Cap to Future Revenue Ratio|Streamex Corp. - Forward P/S Multiple|SRL - Forward P/S Multiple|MV Oil Trust Inc. (MVO) - Price-to-Projected Revenue Ratio|PVL (Permianville Royalty Trust Inc) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple VOC|CRT (crt-crosstimbers.com) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple PRT (PermRock Royalty)|RMCO - Market Cap to Future Revenue Ratio|CKX Lands - Forward Price-to-Revenue Multiple|Forward Price to Sales MTR|BPT - Price-to-Projected Revenue Ratio|Future Price to Revenue PHX|STR: Forward P/S Multiple